• Funding of 1.5 million euros from Bpifrance – Regional Direction of Nantes within the framework of the “R&D Innovation Loan” program.
• Development of a companion diagnostic test to identify HLA-A2 positive patients with non-small cell lung cancer (NSCLC), eligible for treatment with Tedopi® in the next pivotal phase 3 clinical trial in preparation.
Nantes, France – June 20, 2023, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces today that the Company has received non-dilutive funding of €1.5 million from Bpifrance – Direction Régionale de Nantes. The “R&D Innovation Loan” program aims to support the development of a companion diagnostic test as part of the preparation for the phase 3 clinical trial for registration of Tedopi® as a second-line treatment in NSCLC.